Torrent Pharmaceuticals

Torrent Pharmaceuticals
Torrent Pharmaceuticals
Shareholder Return: 3-year, Sales Growth: 3-year CAGR, Return On Equity: 3-year average
At a Glance
  • Shareholder Return
    206%
  • Sales Growth
    12%
  • Return on Equity
    39 %

Why Super 50

Brothers Sudhir and Samir Mehta have resurrected the company after Torrent Pharma lost 70 percent of its business when the erstwhile Soviet Union collapsed in 1991. A good track record of securing approval for new drugs in the US has helped the company. But as pricing pressure in the US impacts Indian pharma companies, a couple of strategic acquisitions made in India are likely to help offset any weakness.



More Stories